Other than delivering anticancer drugs,liposomal formulationswere used to co-encapsulate therapeutic agents for molecular targetingof cancer cells, for example, in nonsmall cell lung cancer (NSCLC),where tyrosine kinase inhibitor (TKI) molecules (e.g., alectinib,crizotinib, ceritinib, brigatinib, and lorlatinib) have gained popularity.95 Gefitinib was the first approved TKI to targetepidermal growth factor receptor (EGFR) and is used in NSCLC patientswith EGFR mutations.96 However, almosthalf of the treated patients eventually develop resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.